Antimicrobial composition

ABSTRACT

The present disclosure relates to the field of antimicrobial compositions. More particularly, it concerns the use of a composition as an antimicrobial agent, the composition comprising ingredients selected from the group consisting of: (i) nona-2,6-dien-1-ol in combination with at least one ingredient selected from the group consisting of 3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineol and 2-isopropyl-5-methylphenol; (ii) gamma-dodecalactone in combination with at least one ingredient selected from the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene, 4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde; (iii) (Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv) cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v) 1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein the ingredients are present in an amount sufficient to provide an antimicrobial effect. The composition and its use for the preparation of antimicrobially active perfuming compositions and consumer products are also objects of the disclosure.

CROSS-REFERENCE

This application is a 371 filing of International Patent ApplicationPCT/EP2017/069804 filed 4 Aug. 2017, which claims the benefit of U.S.Provisional Patent Application No. 62/371,462, which was filed 5 Aug.2016 and European patent application 16186681.9, filed 31 Aug. 2016, thecontents of which are hereby incorporated by reference in theirentirety.

TECHNICAL FIELD

The present disclosure relates to the field of antimicrobialcompositions and their use as antibacterial agents, or their use for thepreparation of antimicrobially active perfuming compositions andconsumer products. More particularly, the present disclosure relates tocompositions selected from the group consisting of: (i)nona-2,6-dien-1-ol in combination with at least one ingredient selectedfrom the group consisting of 3-neopentylpyridine, 2-methylhexan-3-oneoxime, terpineol and 2-isopropyl-5-methylphenol; (ii)gamma-dodecalactonein combination with at least one ingredient selectedfrom the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene,4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde; (iii)(Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv)cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v)1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein theingredients are present in an amount sufficient to provide anantimicrobial effect, wherein the antimicrobial effect is an inhibitionof growth of a bacterial strain selected from the group consisting of:S. aureus and E. coli.

BACKGROUND

Hygiene is a vast subject, which in its fullest meaning goes beyondsimple ‘cleanliness’ to include, in addition to products, processes anddevices, all circumstances and practices, lifestyle habits and premisesthat engender and foster a safe and healthy environment. In particular,hygiene refers to conditions and practices that help to maintain healthand prevent the spread of diseases and therefore includes a specific setof practices associated with this preservation of health, for exampleenvironmental cleaning, sterilization of equipment, hand hygiene, waterand sanitation or safe disposal of medical waste.

To improve hygiene, compounds having antimicrobial effects have beendeveloped. However, the most currently used biocides such asTriclocarban and Triclosan are questioned by consumer or/andauthorities, as such products are suspected to be endocrine disrupters.Consequently, there is a need to find antimicrobial ingredients havingno or lower side effects, while maintaining a good antimicrobialactivity.

In one example, U.S. Pat. No. 7,759,058 discloses an antimicrobialcomposition containing at least 30% by weight of one or more perfumingingredients including nona-2,6-dien-1-ol.

In another example, International Patent Application Publication No.WO2005079573 reports a fragrance composition providing, as expected, anorganoleptic effect but also an antifungal activity in a vapor phase.The antifungal composition comprises at least 50% by weight of the totalcomposition of at least two perfuming ingredients selected from severallists of ingredients comprising among others 2,6-nonadienol and thymol.However, according to those teachings, a large amount of perfumingingredients is required to deliver antimicrobial properties, whichstrongly influences the odor profile of the end-product containing thosecompositions, therefore limiting their use as an antimicrobial agent.

In another example, U.S. Pat. No. 9,339,477 discloses an antimicrobialcomposition for personal cleaning, oral care or hard surface cleaningapplications. Wherein, it was found that compositions comprising thymol,selected propen-2-yl-methyl-cyclohexanols, and a carrier providesynergistic antimicrobial action.

In another example, U.S. Pat. No. 5,453,276 discloses antimicrobialcompositions for controlling P. aeruginosa or P. acnes which containsindole and a naturally occurring substance selected from the groupconsisting of anacardic acid, limonene, beta-pinene, farnesol,beta-citronellol, pine resin, hinokitiol, longifolene, andbeta-caryophyllene.

However, despite the availability of antimicrobial compounds andcompositions, there remains a continuous need to find alternativeantimicrobial compositions and active compounds that are suitable foruse in such compositions. Without intending to be limited to anyparticular theory, the availability of alternatives may reduce the riskof development of microbial resistance and/or insensitivity toparticular antimicrobial compounds.

Therefore, there is still a need to provide compositions having anantimicrobial effect, comprising ingredients having a minor impact onthe overall perfume profile of the product in which the composition isadded while maintaining or even improving the efficacy of thecompositions in order to shorter contact time required for effectiveantimicrobial action.

The present disclosure provides a solution to the above mentionedproblem by using as an antimicrobial agent, compositions selected fromthe group consisting of: (i) nona-2,6-dien-1-ol in combination with atleast one ingredient selected from the group consisting of3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineol and2-isopropyl-5-methylphenol; (ii) gamma-dodecalactone in combination withat least one ingredient selected from the group consisting of1-Methyl-4-(1-methylethenyl)-cyclohexene, 4-Methoxybenzaldehyde, and1,3-Benzodioxole-5-carbaldehyde; (iii)(Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv)cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v)1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein theingredients are present in an amount sufficient to provide anantimicrobial effect, wherein the antimicrobial effect is an inhibitionof growth of a bacterial strain selected from the group consisting of:S. aureus and E. coli. The compositions of the present disclosure canadvantageously be used at low concentrations while a significantantimicrobial effect is surprisingly observed. The use has not beendisclosed or suggested heretofore.

SUMMARY

In one aspect, the present disclosure provides a composition comprisingingredients selected from the group consisting of: (i)nona-2,6-dien-1-ol in combination with at least one ingredient selectedfrom the group consisting of 3-neopentylpyridine, 2-methylhexan-3-oneoxime, terpineol and 2-isopropyl-5-methylphenol; (ii)gamma-dodecalactone in combination with at least one ingredient selectedfrom the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene,4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde; (iii)(Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv)cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v)1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein theingredients are present in an amount sufficient to provide anantimicrobial effect.

In one aspect, the composition provides the antimicrobial effect byinhibiting the growth of bacteria. In one aspect, the antimicrobialeffect is an inhibition of growth of a bacterial strain selected fromthe group consisting of: C. xerosis, S. aureus and E. coli.

In one aspect, the present invention provides a method, comprisingtreating a substrate comprising microbes with a composition according tosome aspects of the present disclosure, in an amount effective toprovide an antimicrobial effect.

In one aspect, the composition comprises nona-2,6-dien-1-ol and at leastone compound selected from the group consisting of 3-neopentylpyridine,terpineol, and 2-methylhexan-3-one oxime. In one aspect, the amountsufficient of the nona-2,6-dien-1-ol is from 75 to 300 ppm, the amountsufficient of the 3-neopentylpyridine is from 75 to 150 ppm, the amountsufficient of the terpineol is from 300 to 600 ppm, and the amountsufficient of the 2-methylhexan-3-one oxime is from 1000 to 1200 ppm.

In one aspect, the composition comprises nona-2,6-dien-1-ol and at leastone compound selected from the group consisting of2-isopropyl-5-methylphenol, and 3-neopentylpyridine. In one aspect, theamount sufficient of the nona-2,6-dien-1-ol is from 75 to 300 ppm, theamount sufficient of the 2-isopropyl-5-methylphenol is from 100 to 200ppm, and the amount sufficient of the 3-neopentylpyridine is from 75 to150 ppm.

In one aspect, the composition comprises gamma-dodecalactone and atleast one compound selected from the group consisting of4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde. In oneaspect, the amount sufficient of the gamma-dodecalactone is from 150 to600 ppm, the amount sufficient of the 4-Methoxybenzaldehyde is from 300to 600 ppm, and the amount sufficient of the1,3-Benzodioxole-5-carbaldehyde is from 300 to 600 ppm.

In one aspect, the composition comprises(Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone. In oneaspect, the amount sufficient of the (Z)-3,7-Dimethyl-2,6-octadien-1-olis from 150 to 300 ppm, and the amount sufficient of thegamma-dodecalactone is from 150 to 600 ppm.

In one aspect, the composition comprisescis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde. In oneaspect, the amount sufficient of the cis-4(Isopropyl)cyclohexanemethanolis from 600 to 2400 ppm, and the amount sufficient of the4-Methoxybenzaldehyde is from 150 to 300 ppm.

In one aspect, the composition comprises 1,3-Benzodioxole-5-carbaldehydeand 4-Methoxybenzaldehyde. In one aspect, the amount sufficient of the1,3-Benzodioxole-5-carbaldehyde is from 75 to 300 ppm, and the amountsufficient of the 4-Methoxybenzaldehyde is from 150 to 300 ppm.

In one aspect, the composition further comprises at least one ingredientselected from the group consisting of a perfumery carrier, a perfumingco-ingredient and mixtures thereof, and optionally at least oneperfumery adjuvant.

In one aspect, the composition is formulated as a consumer product,wherein the consumer product is a perfume, a fabric care product, abody-care product, a cosmetic preparation, a skin-care product, an aircare product or a home care product. In one aspect, the consumer productis a fine perfume, a splash or eau de perfume, a cologne, an shave orafter-shave lotion, a liquid or solid detergent, a fabric softener, afabric refresher, an ironing water, a paper, a bleach, a carpetcleaners, curtain-care products a shampoo, a coloring preparation, acolor care product, a hair shaping product, a dental care product, adisinfectant, an intimate care product, a hair spray, a vanishing cream,a deodorant or antiperspirant, hair remover, tanning or sun product,nail products, skin cleansing, a makeup, a perfumed soap, shower or bathmousse, oil or gel, or a foot/hand care products, a hygiene product, anair freshener, a “ready to use” powdered air freshener, a mold remover,furnisher care, wipe, a dish detergent or hard-surface detergent, aleather care product, a car care product.

DESCRIPTION OF THE INVENTION

In some aspects, the present disclosure provides a compositioncomprising ingredients selected from the group consisting of: (i)nona-2,6-dien-1-ol in combination with at least one ingredient selectedfrom the group consisting of 3-neopentylpyridine, 2-methylhexan-3-oneoxime, terpineol and 2-isopropyl-5-methylphenol; (ii)gamma-dodecalactone in combination with at least one ingredient selectedfrom the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene,4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde; (iii)(Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv)cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v)1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein theingredients are present in an amount sufficient to provide anantimicrobial effect. In some aspects, the antimicrobial effect isunexpected.

In some aspects, the composition provides the antimicrobial effect byinhibiting the growth of bacteria. In one aspect, the antimicrobialeffect is an inhibition of growth of a bacterial strain selected fromthe group consisting of: C. xerosis, S. aureus and E. coli.

In some aspects, the individual ingredients themselves possess anantimicrobial activity; however, the amount sufficient to provide theantimicrobial effect for the individual ingredient when combined in thecomposition is less than the amount sufficient to provide theantimicrobial effect of a given individual ingredient used separately.

In some aspects, the amount sufficient to provide an antimicrobialeffect has no impact on the overall odour profile of the composition.

In some aspects, the composition of the present disclosure, or the usethereof, enables the amount of other bioactive ingredients such as, forexample, triclosan, to be reduced, without impacting the overall perfumeprofile as the antimicrobial effect of the composition is obtained atlow dosages.

In some aspects, the present disclosure provides a use, or a method ofuse of a composition comprising ingredients selected from the groupconsisting of: (i) nona-2,6-dien-1-ol in combination with at least oneingredient selected from the group consisting of 3-neopentylpyridine,2-methylhexan-3-one oxime, terpineol and 2-isopropyl-5-methylphenol;(ii) gamma-dodecalactone in combination with at least one ingredientselected from the group consisting of1-Methyl-4-(1-methylethenyl)-cyclohexene, 4-Methoxybenzaldehyde, and1,3-Benzodioxole-5-carbaldehyde; (iii)(Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone; (iv)cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde; and (v)1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein theingredients are present in an amount sufficient to provide anantimicrobial effect.

By “terpineol”, it is meant the normal meaning in the art; i.e.α-terpineol, β-terpineol, γ-terpineol, terpinen-4-ol or mixture thereof.Alternatively the terpineol presents in the composition is α-terpineolor terpinen-4-ol. Alternatively, terpineol presents in the compositionis α-terpineol. In some aspects, the compound has the followingstructure:

Nona-2,6-dien-1-ol may be in a form of any one of its stereoisomers or amixture thereof. Nona-2,6-dien-1-ol has two carbon-carbon double bonds.Each carbon-carbon double bond of the compound, independently from eachother, can be in a configuration Z or E or a mixture thereof. For thesake of clarity, by the expression “each carbon-carbon double bond ofthe compound, independently from each other, can be in a configuration Zor E or a mixture thereof” it is meant also a composition of mattercomprising the various (E,E), (E,Z), (Z,E) and (Z,Z) isomers ofnona-2,6-dien-1-ol. Alternatively, (2E, 6Z)-nona-2,6-dien-1-ol is used.In some aspects, nona-2,6-dien-1-ol has the following structure:

The ingredient 2-isopropyl-5-methylphenol is also known under the nameThymol, or the compound having the following structure:

The ingredient 2-methylhexan-3-one oxime is also known as vertoxime, orthe compound having the structure:

The ingredient 3-neopentylpyridine is also known as fructopyridine, orthe compound having the structure:

The ingredient 2-isopropyl-5-metylpolyphenol is also known as limonene,or decomposed Portugal.

The ingredient 4-methoxybenzaldehyde is also known as anisic aldeyhde,or the compound having the structure:

The ingredient 1,3-benzodioxole-5-carbaldehyde is also known asheliotropine, or the compound having the structure:

The ingredient (Z)-3,7-dimethyl-2,6-octadien-1-ol is also known asgeraniol, or the compound having the structure:

The ingredient cis-4(isopropyl)cyclohexanemethanol is also known asmayol, or the compound having the structure:

The ingredient gamma-dodecalactone is also known as decal, or thecompound having the structure:

According to any one of the above aspects, the composition is used as anantibacterial agent. A non-limiting list of bacteria for which thecomposition are particularly effective includes Escherichia coli, DSMZ1103 (origin: DSMZ—Deutsche Sammlung von Mikroorganismen undZellkulturen GmbH) or Staphylococcus aureus, DSMZ 1104 (origin:DSMZ—Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH), orCorynebacterium xerosis, ATCC 373 (origin: ATCC—American Type CultureCollection).

By the term “antimicrobial agent”, it is meant the normal meaning in theart; i.e. an agent which kills microorganism or inhibits their growth.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising nona-2,6-dien-1-ol and at least one compoundselected from the group consisting of 3-neopentylpyridine, terpineol,and 2-methylhexan-3-one oxime. Alternatively, in some aspects, thepresent disclosure provides the use of a composition comprisingnona-2,6-dien-1-ol and at least one compound selected from the groupconsisting of 3-neopentylpyridine, terpineol, and 2-methylhexan-3-oneoxime as an antimicrobial agent.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising nona-2,6-dien-1-ol and at least one compoundselected from the group consisting of 2-isopropyl-5-methylphenol, and3-neopentylpyridine. Alternatively, in some aspects, the presentdisclosure provides the use of a composition comprisingnona-2,6-dien-1-ol and at least one compound selected from the groupconsisting of 2-isopropyl-5-methylphenol, and 3-neopentylpyridine as anantimicrobial agent.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising gamma-dodecalactone and at least one compoundselected from the group consisting of 4-Methoxybenzaldehyde, and1,3-Benzodioxole-5-carbaldehyde. Alternatively, in some aspects, thepresent disclosure provides the use of a composition comprisinggamma-dodecalactone and at least one compound selected from the groupconsisting of 4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehydeas an antimicrobial agent.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising gamma-dodecalactone and1-Methyl-4-(1-methylethenyl)-cyclohexene. Alternatively, in someaspects, the present disclosure provides the use of a compositioncomprising gamma-dodecalactone and1-Methyl-4-(1-methylethenyl)-cyclohexene as an antimicrobial agent.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising (Z)-3,7-Dimethyl-2,6-octadien-1-ol andgamma-dodecalactone. Alternatively, in some aspects, the presentdisclosure provides the use of a composition comprising(Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone as anantimicrobial agent.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising cis-4(Isopropyl)cyclohexanemethanol and4-Methoxybenzaldehyde. Alternatively, in some aspects, the presentdisclosure provides the use of a composition comprisingcis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde as anantimicrobial agent.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising 1,3-Benzodioxole-5-carbaldehyde and4-Methoxybenzaldehyde. Alternatively, in some aspects, the presentdisclosure provides the use of a composition comprising1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde as anantimicrobial agent.

In some aspects, the composition used in the present disclosurecomprises nona-2,6-dien-1-ol in an amount above 25 ppm, alternatively inan amount between 25 ppm and 2000 ppm, alternatively in an amountbetween 50 ppm and 1500 ppm. Alternatively, the composition comprisesnona-2,6-dien-1-ol in an amount between 50 ppm and 800 ppm; or in anamount between 200 ppm and 1500 ppm. Alternatively the compositioncomprises nona-2,6-dien-1-ol in an amount between 50 ppm and 500 ppm,alternatively in an amount between 50 ppm and 200 ppm. Alternatively,the composition comprises 75 ppm, 150 ppm, 300 ppm or 600 ppm ofnona-2,6-dien-1-ol.

In some aspects, the composition used in the present disclosurecomprises nona-2,6-dien-1-ol and 3-neopentylpyridine. In some aspects,the composition comprises at least 25 ppm, alternatively at least 75 ppmof nona-2,6-dien-1-ol and at least 25 ppm, alternatively at least 75 ppmof 3-neopentylpyridine. Alternatively, the composition comprisesnona-2,6-dien-1-ol in an amount between 25 and 450 ppm, alternativelybetween 75 and 300 ppm and alternatively between 75 and 150 ppm and3-neopentylpyridine in an amount between 25 and 450 ppm, alternatively75 and 300 ppm and alternatively between 75 and 150 ppm. Alternativelythe composition comprises nona-2,6-dien-1-ol in an amount between 25 and250 ppm, alternatively between 50 and 200 ppm and alternatively between75 and 150 ppm and 3-neopentylpyridine in an amount between 25 and 125ppm, alternatively between 50 and 100 ppm and alternatively between 65and 85 ppm; or the composition comprises nona-2,6-dien-1-ol in an amountbetween 25 and 125 ppm, alternatively between 50 and 100 ppm andalternatively between 65 and 85 ppm and 3-neopentylpyridine in an amountbetween 25 and 250 ppm, alternatively between 50 and 200 ppm andalternatively between 75 and 150 ppm. Alternatively the compositioncomprises (2E,6Z)-nona-2,6-dien-1-ol in an amount between 75 and 150 ppmand 75 ppm of 3-neopentylpyridine; or the composition comprises 75 ppmof (2E,6Z)-nona-2,6-dien-1-ol and 3-neopentylpyridine in an amountbetween 75 and 150 ppm.

In some aspects, the composition used in the present disclosurecomprises nona-2,6-dien-1-ol and 2-methylhexan-3-one oxime. In someaspects, the composition comprises at least 400 ppm, alternatively atleast 600 ppm of nona-2,6-dien-1-ol and at least 100 ppm, alternativelyat least 150 ppm of methylhexan-3-one oxime; or at least 200 ppm,alternatively at least 300 ppm of nona-2,6-dien-1-ol and at least 700ppm, alternatively at least 1200 ppm of methylhexan-3-one oxime; or atleast 25 ppm, alternatively at least 75 ppm of nona-2,6-dien-1-ol and atleast 1800 ppm, alternatively at least 2400 ppm of methylhexan-3-oneoxime. Alternatively, the composition comprises nona-2,6-dien-1-ol in anamount between 25 and 225 ppm and alternatively between 75 and 150 ppmand 2-methylhexan-3-one oxime in an amount between 1800 and 3600 ppm andalternatively between 2100 and 2700 ppm; or nona-2,6-dien-1-ol in anamount between 400 and 1000 ppm, alternatively between 500 and 800 ppmand alternatively between 550 and 650 ppm and 2-methylhexan-3-one oximein an amount between 100 and 800 ppm and alternatively between 150 and600 ppm; or nona-2,6-dien-1-ol in an amount between 200 and 500 ppm,alternatively between 250 and 450 ppm and alternatively between 250 and350 ppm and 2-methylhexan-3-one oxime in an amount between 700 and 2000ppm, alternatively between 800 and 1600 ppm, and alternatively between1000 and 1400 ppm. Alternatively, the composition comprises 300 ppm ofnona-2,6-dien-1-ol and 1200 ppm of 2-methylhexan-3-one oxime.

In some aspects, the composition used in the present disclosurecomprises nona-2,6-dien-1-ol and terpineol. In some aspects, thecomposition comprises at least 200 ppm, alternatively at least 300 ppmof nona-2,6-dien-1-ol and at least 400 ppm, alternatively at least 600ppm of terpineol; or at least 400 ppm, alternatively at least 600 ppm ofnona-2,6-dien-1-ol and at least 200 ppm, alternatively at least 300 ppmof terpineol; or at least 700 ppm, alternatively at least 1200 ppm ofnona-2,6-dien-1-ol and at least 25 ppm, alternatively at least 75 ppm ofterpineol. Alternatively, the composition comprises nona-2,6-dien-1-olin an amount between 200 and 400 ppm and alternatively between 250 and350 ppm and terpineol in an amount between 400 and 1000 ppm,alternatively between 500 and 800 ppm and alternatively between 550 and650 ppm; or nona-2,6-dien-1-ol in an amount between 700 and 2000 ppm,alternatively between 800 and 1600 ppm, and alternatively between 1000and 1400 ppm and terpineol in an amount between 25 and 250 ppm andalternatively between 75 and 150 ppm; or nona-2,6-dien-1-ol in an amountbetween 400 and 1000 ppm, alternatively between 500 and 800 ppm andalternatively between 550 and 650 ppm and terpineol in an amount between200 and 500 ppm, alternatively between 250 and 450 ppm and alternativelybetween 250 and 350 ppm. Alternatively, the composition comprises 600ppm of nona-2,6-dien-1-ol and 300 ppm of terpineol.

In some aspects, the composition used in the present disclosurecomprises nona-2,6-dien-1-ol and 2-isopropyl-5-methylphenol. In someaspects, the composition comprises at least 25 ppm, alternatively atleast 75 ppm of nona-2,6-dien-1-ol and at least 200 ppm, alternativelyat least 300 ppm of 2-isopropyl-5-methylphenol; or at least 100 ppm,alternatively at least 150 ppm of nona-2,6-dien-1-ol and at least 100ppm, alternatively at least 150 ppm of 2-isopropyl-5-methylphenol.Alternatively, the composition comprises nona-2,6-dien-1-ol in an amountbetween 25 and 125 ppm and alternatively between 50 and 100 ppm and2-isopropyl-5-methylphenol in an amount between 200 and 500 ppm,alternatively between 250 and 450 ppm and alternatively between 250 and350 ppm; or nona-2,6-dien-1-ol in an amount between 100 and 400 ppm,alternatively between 150 and 300 ppm and alternatively between 130 and170 ppm and 2-isopropyl-5-methylphenol in an amount between 100 and 225ppm and alternatively between 130 and 170 ppm. Alternatively, thecomposition comprises 150 ppm of nona-2,6-dien-1-ol and 150 ppm of2-isopropyl-5-methylphenol.

In some aspects, the composition used in the present disclosurecomprises gamma-dodecalactone in an amount above 25 ppm, alternativelyin an amount between 25 ppm and 2000 ppm, alternatively in an amountbetween 50 ppm and 1500 ppm. Alternatively, the composition comprisesgamma-dodecalactone in an amount between 50 ppm and 800 ppm; or in anamount between 200 ppm and 1500 ppm. Alternatively the compositioncomprises gamma-dodecalactone in an amount between 50 ppm and 500 ppm,alternatively in an amount between 50 ppm and 200 ppm. Alternatively,the composition comprises 75 ppm, 150 ppm, 300 ppm, 600 ppm, or 700 ppmof gamma-dodecalactone.

In some aspects, the composition used in the present disclosurecomprises gamma-dodecalactone and1-Methyl-4-(1-methylethenyl)-cyclohexene. In some aspects, thecomposition comprises at least 150 ppm, or, alternatively at least 200ppm, alternatively at least 250 ppm, alternatively at least 300 ppm,alternatively at least 350 ppm, alternatively at least 400 ppm,alternatively at least 450 ppm, alternatively at least 500 ppm,alternatively at least 550 ppm, alternatively at least 600 ppm,alternatively at least 650 ppm, alternatively at least 700 ppm ofgamma-dodecalactone and at least 150 ppm, or, alternatively at least 200ppm, alternatively at least 250 ppm, alternatively at least 300 ppm,alternatively at least 350 ppm, alternatively at least 400 ppm,alternatively at least 450 ppm, or alternatively at least 500 ppm of1-Methyl-4-(1-methylethenyl)-cyclohexene. Alternatively, the compositioncomprises gamma-dodecalactone in an amount between 200 and 700 ppm,alternatively between 200 and 600 ppm and alternatively between 300 and600 ppm and 1-Methyl-4-(1-methylethenyl)-cyclohexene in an amountbetween 150 and 500 ppm, alternatively 150 and 500 ppm, alternatively200 and 400 ppm, alternatively 250 and 400 ppm, and alternatively 300and 400 ppm.

In some aspects, the composition comprises gamma-dodecalactone in anamount between 300 and 600 ppm and 300 ppm of1-Methyl-4-(1-methylethenyl)-cyclohexene; or the composition comprises300 ppm of gamma-dodecalactone and1-Methyl-4-(1-methylethenyl)-cyclohexene in an amount between 200 and400 ppm. Alternatively, the composition comprises 600 ppm ofgamma-dodecalactone and 1-Methyl-4-(1-methylethenyl)-cyclohexene in anamount between 200 and 400 ppm.

In some aspects, the composition comprises 300 ppm ofgamma-dodecalactone and 300 ppm1-Methyl-4-(1-methylethenyl)-cyclohexene. In some aspects, thecomposition comprises 600 ppm of gamma-dodecalactone and 300 ppm1-Methyl-4-(1-methylethenyl)-cyclohexene.

In some aspects, the composition used in the present disclosurecomprises gamma-dodecalactone and 4-Methoxybenzaldehyde. In someaspects, the composition comprises at least 50 ppm, or alternatively atleast 100 ppm, or alternatively at least 150 ppm, or alternatively atleast 200 ppm, alternatively at least 250 ppm, alternatively at least300 ppm, alternatively at least 350 ppm, alternatively at least 400 ppm,alternatively at least 450 ppm, alternatively at least 500 ppm,alternatively at least 550 ppm, alternatively at least 600 ppm,alternatively at least 650 ppm, alternatively at least 700 ppm ofgamma-dodecalactone and at least 150 ppm, or, alternatively at least 200ppm, alternatively at least 250 ppm, alternatively at least 300 ppm,alternatively at least 350 ppm, alternatively at least 400 ppm,alternatively at least 450 ppm, or alternatively at least 500 ppm of4-Methoxybenzaldehyde. Alternatively, the composition comprisesgamma-dodecalactone in an amount between 200 and 700 ppm, alternativelybetween 200 and 600 ppm and alternatively between 300 and 600 ppm and4-Methoxybenzaldehyde in an amount between 50 and 500 ppm, alternatively100 and 500 ppm, alternatively 150 and 400 ppm, alternatively 150 and350 ppm, and alternatively 150 and 300 ppm.

In some aspects, the composition comprises gamma-dodecalactone in anamount between 300 and 600 ppm and 150 ppm of 4-Methoxybenzaldehyde; orthe composition comprises 300 ppm of gamma-dodecalactone and4-Methoxybenzaldehyde in an amount between 150 and 300 ppm.Alternatively, the composition comprises 600 ppm of gamma-dodecalactoneand 4-Methoxybenzaldehyde in an amount between 150 and 300 ppm.

In some aspects, the composition comprises 300 ppm ofgamma-dodecalactone and 150 ppm, or alternatively 200 ppm, alternatively250 ppm, alternatively 300 ppm 4-Methoxybenzaldehyde. In some aspects,the composition comprises 600 ppm of gamma-dodecalactone and 150 ppm, oralternatively 200 ppm, alternatively 250 ppm, alternatively 300 ppm4-Methoxybenzaldehyde.

In some aspects, the composition used in the present disclosurecomprises gamma-dodecalactone and 1,3-Benzodioxole-5-carbaldehyde. Insome aspects, the composition comprises at least 150 ppm, or,alternatively at least 200 ppm, alternatively at least 250 ppm,alternatively at least 300 ppm, alternatively at least 350 ppm,alternatively at least 400 ppm, alternatively at least 450 ppm,alternatively at least 500 ppm, alternatively at least 550 ppm,alternatively at least 600 ppm, alternatively at least 650 ppm,alternatively at least 700 ppm of gamma-dodecalactone and at least 150ppm, or, alternatively at least 200 ppm, alternatively at least 250 ppm,alternatively at least 300 ppm, alternatively at least 350 ppm,alternatively at least 400 ppm, alternatively at least 450 ppm,alternatively at least 500 ppm, alternatively at least 550 ppm,alternatively at least 600 ppm, alternatively at least 650 ppm, oralternatively at least 700 ppm of 1,3-Benzodioxole-5-carbaldehyde.Alternatively, the composition comprises gamma-dodecalactone in anamount between 200 and 700 ppm, alternatively between 200 and 600 ppmand alternatively between 300 and 600 ppm and1,3-Benzodioxole-5-carbaldehyde in an amount between 150 and 700 ppm,alternatively 150 and 600 ppm, alternatively 200 and 600 ppm,alternatively 250 and 600 ppm, and alternatively 300 and 600 ppm.

In some aspects, the composition comprises gamma-dodecalactone in anamount between 300 and 600 ppm and 600 ppm of1,3-Benzodioxole-5-carbaldehyde; or the composition comprises 300 ppm ofgamma-dodecalactone and 1,3-Benzodioxole-5-carbaldehyde in an amountbetween 300 and 600 ppm. Alternatively, the composition comprises 600ppm of gamma-dodecalactone and 1,3-Benzodioxole-5-carbaldehyde in anamount between 300 and 600 ppm.

In some aspects, the composition comprises 300 ppm ofgamma-dodecalactone and 300 ppm 1,3-Benzodioxole-5-carbaldehyde. In someaspects, the composition comprises 600 ppm of gamma-dodecalactone and300 ppm 1,3-Benzodioxole-5-carbaldehyde. In some aspects, thecomposition comprises 300 ppm of gamma-dodecalactone and 600 ppm1,3-Benzodioxole-5-carbaldehyde. In some aspects, the compositioncomprises 600 ppm of gamma-dodecalactone and 600 ppm1,3-Benzodioxole-5-carbaldehyde.

In some aspects, the composition used in the present disclosurecomprises (Z)-3,7-Dimethyl-2,6-octadien-1-ol in an amount above 25 ppm,alternatively in an amount between 25 ppm and 2000 ppm, alternatively inan amount between 50 ppm and 1500 ppm. Alternatively, the compositioncomprises (Z)-3,7-Dimethyl-2,6-octadien-1-ol in an amount between 50 ppmand 800 ppm; or in an amount between 200 ppm and 1500 ppm. Alternativelythe composition comprises (Z)-3,7-Dimethyl-2,6-octadien-1-ol in anamount between 50 ppm and 500 ppm, alternatively in an amount between 50ppm and 200 ppm. Alternatively, the composition comprises 75 ppm, 150ppm, 300 ppm, 600 ppm, or 700 ppm of (Z)-3,7-Dimethyl-2,6-octadien-1-ol.

In some aspects, the composition used in the present disclosurecomprises (Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone. Insome aspects, the composition comprises at least 50 ppm, or,alternatively at least 100 ppm, alternatively at least 150 ppm,alternatively at least 200 ppm, alternatively at least 250 ppm,alternatively at least 300 ppm, alternatively at least 350 ppm, oralternatively at least 400 ppm of (Z)-3,7-Dimethyl-2,6-octadien-1-ol andat least 150 ppm, or, alternatively at least 200 ppm, alternatively atleast 250 ppm, alternatively at least 300 ppm, alternatively at least350 ppm, alternatively at least 400 ppm, alternatively at least 450 ppm,or alternatively at least 500 ppm of gamma-dodecalactone. Alternatively,the composition comprises (Z)-3,7-Dimethyl-2,6-octadien-1-ol in anamount between 50 and 500 ppm, alternatively between 100 and 500 ppm andalternatively between 1500 and 5000 ppm and gamma-dodecalactone in anamount between 150 and 500 ppm, alternatively 150 and 500 ppm,alternatively 200 and 400 ppm, alternatively 250 and 400 ppm, andalternatively 300 and 400 ppm.

In some aspects, the composition comprises(Z)-3,7-Dimethyl-2,6-octadien-1-ol in an amount between 150 and 300 ppmand 300 ppm of gamma-dodecalactone; or the composition comprises 150 ppmof (Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone in anamount between 200 and 400 ppm. Alternatively, the composition comprises300 ppm of (Z)-3,7-Dimethyl-2,6-octadien-1-ol and gamma-dodecalactone inan amount between 200 and 400 ppm.

In some aspects, the composition used in the present disclosurecomprises cis-4(Isopropyl)cyclohexanemethanol in an amount above 25 ppm,alternatively in an amount between 25 ppm and 4000 ppm, alternatively inan amount between 50 ppm and 1500 ppm. Alternatively, the compositioncomprises cis-4(Isopropyl)cyclohexanemethanol in an amount between 50ppm and 800 ppm; or in an amount between 500 ppm and 3000 ppm.Alternatively the composition comprisescis-4(Isopropyl)cyclohexanemethanol in an amount between 300 ppm and2500 ppm, alternatively in an amount between 600 ppm and 2400 ppm.Alternatively, the composition comprises 300 ppm, 400 ppm, 500 ppm, 600ppm, 700 ppm, 800 ppm, 900 ppm, 1000 ppm, 1100 ppm, 1200 ppm, 1300 ppm,1400 ppm, 1500 ppm, 1600 ppm, 1700 ppm, 1800 ppm, 1900 ppm, 2000 ppm,2100 ppm, 2200 ppm, 2300 ppm, or 2400 ppm ofcis-4(Isopropyl)cyclohexanemethanol.

In some aspects, the composition used in the present disclosurecomprises cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde.In some aspects, the composition comprises at least 300 ppm, 400 ppm,500 ppm, 600 ppm, 700 ppm, 800 ppm, 900 ppm, 1000 ppm, 1100 ppm, 1200ppm, 1300 ppm, 1400 ppm, 1500 ppm, 1600 ppm, 1700 ppm, 1800 ppm, 1900ppm, 2000 ppm, 2100 ppm, 2200 ppm, 2300 ppm, or 2400 ppm ofcis-4(Isopropyl)cyclohexanemethanol and at least 150 ppm, or,alternatively at least 200 ppm, alternatively at least 250 ppm,alternatively at least 300 ppm, alternatively at least 350 ppm,alternatively at least 400 ppm, alternatively at least 450 ppm, oralternatively at least 500 ppm of 4-Methoxybenzaldehyde. Alternatively,the composition comprises cis-4(Isopropyl)cyclohexanemethanol in anamount between 50 and 500 ppm, alternatively between 100 and 500 ppm andalternatively between 1500 and 5000 ppm and 4-Methoxybenzaldehyde in anamount between 150 and 500 ppm, alternatively 150 and 500 ppm,alternatively 200 and 400 ppm, alternatively 250 and 400 ppm, andalternatively 300 and 400 ppm.

In some aspects, the composition comprisescis-4(Isopropyl)cyclohexanemethanol in an amount between 600 and 2400ppm and 300 ppm of 4-Methoxybenzaldehyde; or the composition comprises600 ppm of cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehydein an amount between 150 and 300 ppm. Alternatively, the compositioncomprises 1200 ppm of cis-4(Isopropyl)cyclohexanemethanol and4-Methoxybenzaldehyde in an amount between 150 and 300 ppm.Alternatively, the composition comprises 2400 ppm ofcis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde in anamount between 150 and 300 ppm.

In some aspects, the composition used in the present disclosurecomprises 1,3-Benzodioxole-5-carbaldehyde in an amount above 25 ppm,alternatively in an amount between 25 ppm and 2000 ppm, alternatively inan amount between 50 ppm and 1500 ppm. Alternatively, the compositioncomprises 1,3-Benzodioxole-5-carbaldehyde in an amount between 50 ppmand 800 ppm; or in an amount between 50 ppm and 3000 ppm. Alternativelythe composition comprises 1,3-Benzodioxole-5-carbaldehyde in an amountbetween 25 ppm and 600 ppm, alternatively in an amount between 50 ppmand 600 ppm. Alternatively, the composition comprises 50 ppm, 60 ppm, 70ppm, 80 ppm, 90 ppm, 100 ppm, 110 ppm, 120 ppm, 130 ppm, 140 ppm, 150ppm, 160 ppm, 170 ppm, 180 ppm, 190 ppm, 200 ppm, 250 ppm, or 300 ppm of1,3-Benzodioxole-5-carbaldehyde.

In some aspects, the composition used in the present disclosurecomprises 1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde. Insome aspects, the composition comprises at least 50 ppm, or,alternatively at least 100 ppm, alternatively at least 150 ppm,alternatively at least 200 ppm, alternatively at least 250 ppm,alternatively at least 300 ppm, alternatively at least 350 ppm, oralternatively at least 400 ppm of 1,3-Benzodioxole-5-carbaldehyde and atleast 150 ppm, or, alternatively at least 200 ppm, alternatively atleast 250 ppm, alternatively at least 300 ppm, alternatively at least350 ppm, alternatively at least 400 ppm, alternatively at least 450 ppm,or alternatively at least 500 ppm of 4-Methoxybenzaldehyde.Alternatively, the composition comprises 1,3-Benzodioxole-5-carbaldehydein an amount between 50 and 500 ppm, alternatively between 75 and 300ppm and 4-Methoxybenzaldehyde in an amount between 150 and 500 ppm,alternatively 150 and 500 ppm, alternatively 200 and 400 ppm,alternatively 250 and 400 ppm, and alternatively 300 and 400 ppm.

In some aspects, the composition comprises1,3-Benzodioxole-5-carbaldehyde in an amount between 75 and 300 ppm and300 ppm of 4-Methoxybenzaldehyde; or the composition comprises 75 ppm of1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde in an amountbetween 150 and 300 ppm. Alternatively, the composition comprises 300ppm of 1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde in anamount between 150 and 300 ppm.

As shown in the examples below, the compositions presented hereindemonstrate an antimicrobial effect. According to a particular aspect,the compositions even provide a synergistic antimicrobial effect; i.e.an effect which is superior to the simple sum or addition of theantimicrobial effect expected when the two ingredients of thecomposition would have been admixed in the desired concentration. Inother words, in such cases, antibacterial activity of the combination ofboth ingredients is greater than the sum of activities of the individualingredients. The synergistic effect may be determined firstly bymeasuring the Minimal Inhibitory Concentration (MIC) for each ingredientin isolation and in the combination. These MIC values can then be usedto calculate the Fractional Inhibitory Index (FIC) for each agent andthen the overall ΣFIC for the combination, as reported in Garcia L. S.,Clinical Microbiology Procedures Handbook, pg. 140-162, 3^(rd) Edition(2010), ASM Press, Washington D.C. A composition is considered to havean additive antimicrobial effect also known as a partial antimicrobialsynergistic effect when FIC Index in below 1. For FIC Index below 0.5,the composition is considered to have a synergistic antimicrobialeffect.

The use of the compositions as defined here-in is particularlyadvantageous to limit or control the growth of microorganism such asbacteria. The antimicrobial effect is one of the main requirements ofhygiene products such as body care or home care products.

As mentioned above, the disclosure concerns the use of the compositionsas defined above as an antimicrobial agent.

In some aspects, the present disclosure provides a non-therapeuticmethod of affecting microbial activity, the method comprising treating asubstrate comprising microbes with a composition comprisingnona-2,6-dien-1-ol and at least one compound selected from the groupconsisting of 3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineoland 2-isopropyl-5-methylphenol, wherein the substrate is treated withthe composition in an amount sufficient to provide an antimicrobialeffect.

In some aspects, the present disclosure provides a non-therapeuticmethod of affecting microbial activity, the method comprising treating asubstrate comprising microbes with a composition comprisinggamma-dodecalactone in combination with at least one ingredient selectedfrom the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene,4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde, wherein thesubstrate is treated with the composition in an amount sufficient toprovide an antimicrobial effect.

In some aspects, the present disclosure provides a non-therapeuticmethod of affecting microbial activity, the method comprising treating asubstrate comprising microbes with a composition comprising1,3-Benzodioxole-5-carbaldehyde and gamma-dodecalactone, wherein thesubstrate is treated with the composition in an amount sufficient toprovide an antimicrobial effect.

In some aspects, the present disclosure provides a non-therapeuticmethod of affecting microbial activity, the method comprising treating asubstrate comprising microbes with a composition comprising1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein thecomposition is present in an amount sufficient to provide anantimicrobial effect.

In some aspects, the present disclosure provides a non-therapeuticmethod of affecting microbial activity, the method comprising treating asubstrate comprising microbes with a composition comprising acomposition comprising 1,3-Benzodioxole-5-carbaldehyde and4-Methoxybenzaldehyde, wherein the composition is present in an amountsufficient to provide an antimicrobial effect.

By the term “affecting”, it is meant the inhibition of growth ofmicroorganisms or the killing of microorganisms.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising nona-2,6-dien-1-ol and at least one compoundselected from the group consisting of 3-neopentylpyridine, terpineol,and 2-methylhexan-3-one oxime.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising nona-2,6-dien-1-ol and at least one compoundselected from the group consisting of 2-isopropyl-5-methylphenol, and3-neopentylpyridine.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising gamma-dodecalactone and at least one compoundselected from the group consisting of 4-Methoxybenzaldehyde, and1,3-Benzodioxole-5-carbaldehyde.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising gamma-dodecalactone and1-Methyl-4-(1-methylethenyl)-cyclohexene.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising 1,3-Benzodioxole-5-carbaldehyde andgamma-dodecalactone.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising 1,3-Benzodioxole-5-carbaldehyde and4-Methoxybenzaldehyde.

In some aspects, the present disclosure provides an antimicrobialcomposition comprising 1,3-Benzodioxole-5-carbaldehyde and4-Methoxybenzaldehyde.

In some aspects, the present disclosure provides a perfuming compositioncomprising:

-   -   a) a composition comprising nona-2,6-dien-1-ol and a least one        compound selected from the group consisting of        3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineol and        2-isopropyl-5-methylphenol, wherein the composition is present        in an amount sufficient to provide an antimicrobial effect;    -   b) at least one ingredient selected from the group consisting of        a perfumery carrier, a perfuming co-ingredient and mixtures        thereof, and    -   c) optionally at least one perfumery adjuvant.

In some aspects, the present disclosure provides a perfuming compositioncomprising:

-   -   a) a composition comprising at least gamma-dodecalactone in        combination with at least one ingredient selected from the group        consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene,        4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde,        wherein the composition is present in an amount sufficient to        provide an antimicrobial effect;    -   b) at least one ingredient selected from the group consisting of        a perfumery carrier, a perfuming co-ingredient and mixtures        thereof; and    -   c) optionally at least one perfumery adjuvant.

In some aspects, the present disclosure provides a perfuming compositioncomprising:

-   -   a) a composition comprising at least        1,3-Benzodioxole-5-carbaldehyde and gamma-dodecalactone, wherein        the composition is present in an amount sufficient to provide an        antimicrobial effect;    -   b) at least one ingredient selected from the group consisting of        a perfumery carrier, a perfuming co-ingredient and mixtures        thereof; and    -   c) optionally at least one perfumery adjuvant.

In some aspects, the present disclosure provides a perfuming compositioncomprising:

-   -   a) a composition comprising at least        cis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde,        wherein the composition is present in an amount sufficient to        provide an antimicrobial effect;    -   b) at least one ingredient selected from the group consisting of        a perfumery carrier, a perfuming co-ingredient and mixtures        thereof; and    -   c) optionally at least one perfumery adjuvant.

In some aspects, the present disclosure provides a perfuming compositioncomprising:

-   -   a) a composition comprising at least        1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde,        wherein the composition is present in an amount sufficient to        provide an antimicrobial effect;    -   b) at least one ingredient selected from the group consisting of        a perfumery carrier, a perfuming co-ingredient and mixtures        thereof, and    -   c) optionally at least one perfumery adjuvant.

In some aspects, the present disclosure provides a perfuming consumerproduct comprising a composition comprising nona-2,6-dien-1-ol and aleast one compound selected from the group consisting of3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineol and2-isopropyl-5-methylphenol, wherein the composition is present in anamount sufficient to provide an antimicrobial effect.

In some aspects, the present disclosure provides a perfuming consumerproduct comprising a composition comprising gamma-dodecalactone incombination with at least one ingredient selected from the groupconsisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene,4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde, wherein thecomposition is present in an amount sufficient to provide anantimicrobial effect.

In some aspects, the present disclosure provides a perfuming consumerproduct comprising a composition comprising1,3-Benzodioxole-5-carbaldehyde in combination and gamma-dodecalactone,wherein the composition is present in an amount sufficient to provide anantimicrobial effect.

In some aspects, the present disclosure provides a perfuming consumerproduct comprising a composition comprisingcis-4(Isopropyl)cyclohexanemethanol and 4-Methoxybenzaldehyde, whereinthe composition is present in an amount sufficient to provide anantimicrobial effect.

In some aspects, the present disclosure provides a perfuming consumerproduct comprising a composition comprising1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein thecomposition is present in an amount sufficient to provide anantimicrobial effect.

The amounts of each ingredient in the antimicrobial composition are asdefined above.

By “perfumery carrier” we mean here a material which is practicallyneutral from a perfumery point of view, i.e. which does notsignificantly alter the organoleptic properties of perfumingingredients. The carrier may be a liquid or a solid.

As liquid carrier one may cite, as non-limiting examples, an emulsifyingsystem, i.e. a solvent and a surfactant system, or a solvent commonlyused in perfumery. A detailed description of the nature and type ofsolvents commonly used in perfumery cannot be exhaustive. However, onecan cite as non-limiting examples solvents such as butylene or propyleneglycols, glycerol, dipropyleneglycol and its monoether,1,2,3-propanetriyl triacetate, dimethyl glutarate, dimethyl adipate1,3-diacetyloxypropan-2-yl acetate, diethyl phthalate, isopropylmyristate, benzyl benzoate, benzyl alcohol, 2-(2-ethoxyethoxy)-1-ethano,tri-ethyl citrate or mixtures thereof, which are the most commonly used.For the compositions which comprise both a perfumery carrier and aperfumery co-ingredient, other suitable perfumery carriers than thosepreviously specified, can be also ethanol, water/ethanol mixtures,limonene or other terpenes, isoparaffins such as those known under thetrademark Isopar® (origin: Exxon Chemical) or glycol ethers and glycolether esters such as those known under the trademark Dowanol® (origin:Dow Chemical Company), or hydrogenated castors oils such as those knownunder the trademark Cremophor® RH 40 (origin: BASF).

As solid carrier it is meant a material where the perfuming compositionor some element of the perfuming composition can be chemically orphysically bound. In general such solid carrier are employed either tostabilize the composition, either to control the rate of evaporation ofthe compositions or of some ingredients. The employment of solid carrieris of current use in the art and a person skilled in the art knows howto reach the desired effect. However by way of non-limiting example assolid carriers one may cite absorbing gums or polymers or inorganicmaterial, such as porous polymers, cyclodextrines, wood based materials,organic or inorganic gels, clays, gypsum talc or zeolites.

As other non-limiting example of solid carrier one may citeencapsulating materials. Examples of such materials may comprisewall-forming and plasticizing materials, such as mono, di- ortrisaccharides, natural or modified starches, hydrocolloids, cellulosederivatives, polyvinyl acetates, polyvinylalcohols, proteins or pectins,or yet the materials cited in reference texts such as H. Scherz,Hydrokolloide: Stabilisatoren, Dickungs—und Geliermittel inLebensmitteln, Band 2 der Schriftenreihe Lebensmittelchemie,Lebensmittelqualitat, Behr's Verlag GmbH & Co., Hamburg, 1996. Theencapsulation is a well-known process to a person skilled in the art,and may be performed, for instance, using techniques such asspray-drying, agglomeration or yet extrusion; or consists of a coatingencapsulation, including coacervation and complex coacervationtechnique. As non-limiting examples one may cite in particular thecore-shell encapsulation with resins of the aminoplast, polyamide,polyester, polyurea or polyurethane type or a mixture thereof (all ofthe resins are well known to a person skilled in the art) usingtechniques like phase separation process induced by polymerization, byinterfacial polymerization, by coacervation or altogether (all of thetechniques are have been described in the prior art), and optionally inpresence of polymeric stabilizer or a cationic copolymer.

In particular, as resins one may cite the ones produced by thepolycondensation of an aldehyde (e.g. formaldehyde,2,2-dimethoxyethanal, glyoxal, glyoxylic acid or glycolaldehyde andmixtures thereof) with an amine, namely urea, benzoguanamine,glycoluryl, melamine, methylol melamine, methylated methylol melamine,guanazole and the like, as well as mixtures thereof. Alternatively onemay use preformed resins alkylolated polyamines such as thosecommercially available under the trademark Urac® (origin: CytecTechnology Corp.), Cymel® (origin: Cytec Technology Corp.), Urecoll® orLuracoll® (origin: BASF).

In particular, as resins one may cite the ones produced by thepolycondensation of an a polyol, like glycerol, and a polyisocyanate,like a trimer of hexamethylene diisocyanate, a trimer of isophoronediisocyanate or xylylene diisocyanate or a Biuret of hexamethylenediisocyanate or a trimer of xylylene diisocyanate withtrimethylolpropane (known with the tradename of Takenate®, origin:Mitsui Chemicals), among which a trimer of xylylene diisocyanate withtrimethylolpropane and a Biuret of hexamethylene diisocyanate.

Some of the seminal literature related to the encapsulation of perfumesby polycondensation of amino resins, namely melamine based resins, withaldehydes is represented by articles such as those published by K.Dietrich et al. in Acta Polymerica, 1989, vol. 40, pages 243, 325 and683, as well as 1990, vol. 41, page 91. Such articles already describethe various parameters affecting the preparation of such core-shellmicrocapsules following prior art methods that are also further detailedand exemplified in the patent literature. U.S. Pat. No. 4,396,670, tothe Wiggins Teape Group Limited is a pertinent early example of thelatter. Since then, many other authors and creators have enriched theliterature in this field and it would be impossible to cover allpublished developments here, but the general knowledge in this type ofencapsulation is very significant. More recent publications ofpertinence, which also address the suitable uses of such microcapsules,are represented for example by the article of H. Y. Lee et al. inJournal of Microencapsulation, 2002, vol. 19, pages 559-569,international patent publication WO 01/41915 or yet the article of S.Bône et al. in Chimia, 2011, vol. 65, pages 177-181.

Perfuming co-ingredients, when present in the perfuming composition, areother than nona-2,6-dien-1-ol, 3-neopentylpyridine, 2-methylhexan-3-oneoxime, terpineol or 2-isopropyl-5-methylphenol. Moreover, by “perfumingco-ingredient” it is meant here a compound, which is used in a perfumingpreparation or a composition to impart a hedonic effect. In other wordssuch a co-ingredient, to be considered as being a perfuming one, must berecognized by a person skilled in the art as being able to impart ormodify in a positive or pleasant way the odor of a composition, and notjust as having an odor.

The nature and type of the perfuming co-ingredients do not warrant amore detailed description here, which in any case would not beexhaustive, the skilled person being able to select them on the basis ofhis general knowledge and according to intended use or application andthe desired organoleptic effect. In general terms, these perfumingco-ingredients belong to chemical classes as varied as alcohols,lactones, aldehydes, ketones, esters, ethers, acetates, nitriles,terpenoids, nitrogenous or sulphurous heterocyclic compounds andessential oils, and the perfuming co-ingredients can be of natural orsynthetic origin.

In particular one may cite perfuming co-ingredients which are commonlyused in perfume formulations, such as:

-   -   Aldehydic ingredients: decanal, dodecanal, 2-methyl-undecanal,        10-undecenal, octanal and/or nonenal;    -   Aromatic-herbal ingredients: eucalyptus oil, camphor,        eucalyptol, menthol and/or alpha-pinene;    -   Balsamic ingredients: coumarine, ethylvanillin and/or vanillin;    -   Citrus ingredients: dihydromyrcenol, citral, orange oil, linalyl        acetate, citronellyl nitrile, orange terpenes, limonene,        1-P-menthen-8-yl acetate and/or 1,4(8)-P-menthadiene;    -   Floral ingredients: Methyl dihydrojasmonate, linalool,        Citronellol, phenylethanol,        3-(4-tert-butylphenyl)-2-methylpropanal, hexylcinnamic aldehyde,        benzyl acetate, benzyl salicylate,        tetrahydro-2-isobutyl-4-methyl-4(2H)-pyranol, beta ionone,        methyl 2-(methylamino)benzoate,        (E)-3-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one,        hexyl salicylate, 3,7-dimethyl-1,6-nonadien-3-ol,        3-(4-isopropylphenyl)-2-methylpropanal, verdyl acetate,        geraniol, P-menth-1-en-8-ol, 4-(1,1-dimethylethyl)-1-cyclohexyle        acetate, 1,1-dimethyl-2-phenylethyl acetate,        4-cyclohexyl-2-methyl-2-butanol, amyl salicylate, high cis        methyl dihydrojasmonate, 3-methyl-5-phenyl-1-pentanol, verdyl        proprionate, geranyl acetate, tetrahydro linalool,        cis-7-P-menthanol, Propyl (S)-2-(1,1-dimethylpropoxy)propanoate,        2-methoxynaphthalene, 2,2,2-trichloro-1-phenylethyl acetate,        4/3-(4-hydroxy-4-methylpentyl)-3-cyclohexene-1-carbaldehyde,        amylcinnamic aldehyde, 4-phenyl-2-butanone, isononyle acetate,        4-(1,1-dimethylethyl)-1-cyclohexyl acetate, verdyl isobutyrate        and/or mixture of methylionones isomers;    -   Fruity ingredients: gamma ungamma-dodecalactoneactone,        4-decanolide, ethyl 2-methyl-pentanoate, hexyl acetate, ethyl        2-methylbutanoate, gamma nonalactone, allyl heptanoate,        2-phenoxyethyl isobutyrate, ethyl        2-methyl-1,3-dioxolane-2-acetate and/or diethyl 1,4-cyclohexane        dicarboxylate;    -   Green ingredients: 2,4-Dimethyl-3-cyclohexene-1-carbaldehyde,        2-tert-butyl-1-cyclohexyl acetate, styrallyl acetate, allyl        (2-methylbutoxy)acetate, 4-methyl-3-decen-5-ol, diphenyl ether,        (Z)-3-hexen-1-ol and/or        1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one;    -   Musk ingredients: 1,4-dioxa-5,17-cycloheptadecanedione,        pentadecenolide, 3-Methyl-5-cyclopentadecen-1-one,        1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta-g-2-benzopyrane,        (1S,1′R)-2-[1-(3′,3′-dimethyl-1′-cyclohexyl)ethoxy]-2-methylpropyl        propanoate, pentadecanolide and/or        (1S,1′R)-[1-(3′,3′-Dimethyl-1′-cyclohexyl)ethoxycarbonyl]methyl        propanoate;    -   Woody ingredients:        1-(octahydro-2,3,8,8-tetramethyl-2-naphtalenyl)-1-ethanone,        patchouli oil, terpenes fractions of patchouli oil,        (1′R,E)-2-ethyl-4-(2′,2′,3′-trimethyl-3′-cyclopenten-1′-yl)-2-buten-1-ol,        2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten-1-ol,        Methyl cedryl ketone,        5-(2,2,3-trimethyl-3-cyclopentenyl)-3-methylpentan-2-ol,        1-(2,3,8,8-tetramethyl-1,2,3,4,6,7,8,8a-octahydronaphthalen-2-yl)ethan-1-one        and/or isobornyl acetate;    -   Other ingredients (e.g. amber, powdery spicy or watery):        dodecahydro-3a,6,6,9a-tetramethyl-naphtho[2,1-b]furan and any of        its stereoisomers, heliotropin, anisic aldehyde, eugenol,        cinnamic aldehyde, clove oil,        3-(1,3-benzodioxol-5-yl)-2-methylpropanal and/or        3-(3-isopropyl-1-phenyl)butanal.

Perfuming co-ingredients may not be limited to the above mentioned, andmany other of these co-ingredients are in any case listed in referencetexts such as the book by S. Arctander, Perfume and Flavor Chemicals,1969, Montclair, N.J., USA, or its more recent versions, or in otherworks of a similar nature, as well as in the abundant patent literaturein the field of perfumery. It is also understood that the co-ingredientsmay also be compounds known to release in a controlled manner varioustypes of perfuming compounds.

By “perfumery adjuvant” what is meant is an ingredient capable ofimparting additional added benefit such as a color, a particular lightresistance, chemical stability, etc. A detailed description of thenature and type of adjuvant commonly used in perfumery cannot beexhaustive, but it has to be mentioned that the ingredients are wellknown to a person skilled in the art. However, one may cite as specificnon-limiting examples the following: viscosity agents (e.g. surfactants,thickeners, gelling and/or rheology modifiers), stabilizing agents (e.g.preservatives, antioxidant, heat/light and or buffers or chelatingagents, such as BHT), color agents (e.g. dyes and/or pigments),preservative (e.g. antibacterial or antimicrobial or antifungi or antiirritant agents), abrasives, skin cooling agents, fixatives, insectrepellants, ointments, vitamins and mixture thereof.

It is understood that a person skilled in the art is perfectly able todesign optimal formulations for the desired effect by admixing the abovementioned components of a perfuming composition, simply by applying thestandard knowledge of the art as well as by trial and errormethodologies.

A perfuming composition consisting of at least one antimicrobialcomposition as defined above and at least one perfumery carrierrepresents a particular aspect of the disclosure as well as a perfumingcomposition comprising at least one antimicrobial composition as definedabove, at least one perfumery carrier, at least one perfumeryco-ingredient, and optionally at least one perfumery adjuvant.

For the sake of clarity, it is also understood that any mixtureresulting directly from a chemical synthesis, e.g. a reaction mediumwithout an adequate purification, in which the compound of the presentdisclosure would be involved as a starting, intermediate or end-productcould not be considered as a perfuming composition according to thedisclosure as far as the mixture does not provide the inventive compoundin a suitable form for perfumery. Thus, unpurified reaction mixtures aregenerally excluded from the present disclosure unless otherwisespecified.

Furthermore, the antimicrobial composition, as defined above, can alsobe advantageously used in all the fields of modern perfumery, i.e. fineor functional perfumery, to positively impart or modify the odor of aconsumer product into which the compound (I) is added. Consequently,another object of the present disclosure is represented by a perfumingconsumer product comprising, at least one antimicrobial compositioncomprising nona-2,6-dien-1-ol and a least a compound selected from thegroup consisting of 3-neopentylpyridine, 2-methylhexan-3-one oxime,terpineol and 2-isopropyl-5-methylphenol. Alternatively, the perfumingconsumer product comprises at least one antimicrobial compositioncomprising nona-2,6-dien-1-ol and a least a compound selected from thegroup consisting of 3-neopentylpyridine and 2-methylhexan-3-one oxime.

The above-composition can be added as such or as part of the presentdisclosure's perfuming composition.

For the sake of clarity, it has to be mentioned that, by “perfumingconsumer product” it is meant a consumer product which is expected todeliver at least a pleasant perfuming effect to the surface to which itis applied (e.g. skin, hair, textile, or home surface) or in the air. Inother words, a perfuming consumer product according to the disclosure isa perfumed consumer product which comprises the functional formulation,as well as optionally additional benefit agents, corresponding to thedesired consumer product, e.g. a detergent or an air freshener, and anolfactive effective amount of at least one disclosure's compound. Forthe sake of clarity, the perfuming consumer product is a non-edibleproduct.

The nature and type of the constituents of the perfuming consumerproduct do not warrant a more detailed description here, which in anycase would not be exhaustive, the skilled person being able to selectthem on the basis of his general knowledge and according to the natureand the desired effect of the product.

Non-limiting examples of suitable perfuming consumer product can be aperfume, such as a fine perfume, a splash or eau de perfume, a cologneor a shave or after-shave lotion; a fabric care product, such as aliquid or solid detergent, a fabric softener, a fabric refresher, anironing water, a paper, or a bleach, carpet cleaners, curtain-careproducts; a body-care product, such as a hair care product (e.g. ashampoo, a coloring preparation or a hair spray, a color care product,hair shaping product, a dental care product), a disinfectant, anintimate care product; a cosmetic preparation (e.g. a skin cream orlotion, a vanishing cream or a deodorant or antiperspirant (e.g. a sprayor roll on), hair remover, tanning or sun or after sun product, nailproducts, skin cleansing, a makeup); or a skin-care product (e.g. aperfumed soap, shower or bath mousse, oil or gel, or a hygiene productor a foot/hand care products); an air care product, such as an airfreshener or a “ready to use” powdered air freshener which can be usedin the home space (rooms, refrigerators, cupboards, shoes or car) and/orin a public space (halls, hotels, malls, etc.); or a home care product,such as a mold remover, furnisher care, wipe, a dish detergent orhard-surface (e.g. a floor, bath, sanitary or a windows) detergent; aleather care product; a car care product, such as a polish, waxes or aplastic cleaners. Alternatively, in some aspects, the consumer productsare body care or home care products.

Some of the above-mentioned perfuming consumer products may represent anaggressive medium for the disclosure's composition, so that it may benecessary to protect the latter from premature decomposition, forexample by encapsulation or by chemically binding it to another chemicalwhich is suitable to release the disclosure's ingredient upon a suitableexternal stimulus, such as an enzyme, light, heat or a change of pH.

The proportions in which the composition according to the disclosure canbe incorporated into the various aforementioned products or compositionsvary within a wide range of values. These values are dependent on thenature of the article to be perfumed and on the desired organolepticeffect as well as on the nature of the co-ingredients when the compoundsaccording to the disclosure are mixed with perfuming co-ingredients,solvents or additives commonly used in the art.

For example, in the case of perfuming compositions, typicalconcentrations are in the order of 0.001% to 10% by weight, or evenmore, of the disclosure's composition based on the weight of thecomposition into which they are incorporated. Concentrations lower thanthese, such as in the order of 0.01% to 1% by weight, can be used whenthese compounds are incorporated into perfuming consumer products,percentage being relative to the weight of the article.

In some aspects, the present disclosure provides the use or a method ofusing a composition comprising nona-2,6-dien-1-ol and at least onecompound selected from the group consisting of 3-neopentylpyridine,2-methylhexan-3-one oxime, terpineol and 2-isopropyl-5-methylphenol,wherein the composition is present in an amount sufficient to provide anantimicrobial effect, for the preparation of an antimicrobially activeconsumer product.

In some aspects, the present disclosure provides the use or a method ofusing a composition comprising gamma-dodecalactone in combination withat least one ingredient selected from the group consisting of1-Methyl-4-(1-methylethenyl)-cyclohexene, 4-Methoxybenzaldehyde, and1,3-Benzodioxole-5-carbaldehyde, wherein the composition is present inan amount sufficient to provide an antimicrobial effect, for thepreparation of an antimicrobially active consumer product.

In some aspects, the present disclosure provides the use or a method ofusing a composition comprising 1,3-Benzodioxole-5-carbaldehyde andgamma-dodecalactone, wherein the composition is present in an amountsufficient to provide an antimicrobial effect, for the preparation of anantimicrobially active consumer product.

In some aspects, the present disclosure provides the use or a method ofusing a composition comprising 1,3-Benzodioxole-5-carbaldehyde and4-Methoxybenzaldehyde, wherein the composition is present in an amountsufficient to provide an antimicrobial effect, for the preparation of anantimicrobially active consumer product.

In some aspects, the present disclosure provides the use or a method ofusing a composition comprising a composition comprising1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde, wherein thecomposition is present in an amount sufficient to provide anantimicrobial effect, for the preparation of an antimicrobially activeconsumer product.

By the expression “antimicrobially active consumer product” it is meantthe normal meaning in the art: i.e. a consumer product which is expectedto inhibit the growth of microorganism or to kill the microorganismpresent on the surface to which it is applied (e.g. skin, hair, textile,or home surface).

The disclosure also provides particular methods of use includingcounteracting microbial activity in a perfuming or consumer product inparticular by circumventing the presence of chlorinated biocides in suchproducts. These methods comprise adding to or incorporating in suchproducts a composition selected from the group consisting of: (i) acomposition comprising at least nona-2,6-dien-1-ol in combination withat least one ingredient selected from the group consisting of3-neopentylpyridine, 2-methylhexan-3-one oxime, terpineol and2-isopropyl-5-methylphenol; (ii) a composition comprising at leastgamma-dodecalactone in combination with at least one ingredient selectedfrom the group consisting of 1-Methyl-4-(1-methylethenyl)-cyclohexene,4-Methoxybenzaldehyde, and 1,3-Benzodioxole-5-carbaldehyde; (iii) acomposition comprising at least 1,3-Benzodioxole-5-carbaldehyde andgamma-dodecalactone; (iv) a composition comprising at least1,3-Benzodioxole-5-carbaldehyde and 4-Methoxybenzaldehyde; and (v) acomposition comprising at least 1,3-Benzodioxole-5-carbaldehyde and4-Methoxybenzaldehyde, wherein the composition provides an antimicrobialeffect. Thus, the use of chlorinated biocides can be avoided oreliminated.

EXAMPLES

The disclosure will now be described in further detail by way of thefollowing examples, wherein the abbreviations have the usual meaning inthe art and the temperatures are indicated in degrees centigrade (° C.).

Example 1

Measurement of the Antimicrobial Activity of a Composition According tothe Present Disclosure

Method to Assess Antimicrobial Activity

The method below allows evaluating antimicrobial activity of differentraw materials in combination. The Fractional Inhibitory ConcentrationIndex (FIC Index) is a measure of activity (Garcia L. S., ClinicalMicrobiology Procedures Handbook, pg. 140-162, 3^(rd) Edition (2010),ASM Press, Washington D.C.) and is calculated according to the formulabelow:

${\Sigma\;{FIC}\mspace{14mu}{Index}} = {\frac{{MIC}_{A}\mspace{14mu}{combination}}{{MIC}_{A}\mspace{14mu}{alone}} + \frac{{MIC}_{B}\mspace{14mu}{combination}}{{MIC}_{B}\mspace{14mu}{alone}}}$where (MIC_(A) alone) and (MIC_(B) alone) are the Minimal InhibitoryConcentrations (MIC) of individual ingredients A and B when used inisolation, respectively; whereas (MIC_(A) combination) and (MIC_(B)combination) are the Minimal Inhibitory Concentrations of materials Aand B when tested in combination. Ingredient A corresponds tonona-2,6-dien-1-ol and ingredient B stands for 3-neopentylpyridine,2-methylhexan-3-one oxime, terpineol or 2-isopropyl-5-methylphenol.

The Minimal Inhibitory Concentration of a material is defined as thelowest concentration of an agent which can inhibit visible bacterialgrowth (CLSI M08-A8 Methods for dilution Antimicrobial SusceptibilityTest for Bacteria That Grow Aerobically; Approved Standard-EighthEdition).

A combination of raw materials is considered to exert a partiallysynergistic antimicrobial effect (or also called antimicrobial additiveeffect) if the FIC Index is inferior to 1 and a synergisticantimicrobial effect if the FIC Index is inferior or equal to 0.5. FICIndex values inferior or equal to 4 but superior or equal to 1 indicateindifference, whereas FIC index values superior to 4 indicate antagonism(Garcia L. S., Clinical Microbiology Procedures Handbook, pg. 140-162,3^(rd) Edition (2010), ASM Press, Washington D.C.).

Preparation of Bacteria Material

Bacterial suspensions of E. coli DSMZ 1103 and S. aureus DSMZ 1104 wereprepared as follows: a frozen stock aliquot was streaked on a TrypticSoy Agar plate, which was then incubated at 37° C. for 24 hours. Asingle bacterial colony was picked and inoculated into 50 ml of MuellerHinton Broth contained in a 100 ml-flask. Incubation was performedovernight at 37° C., under agitation (160 rpm). The following day, theovernight culture was diluted into 50 ml of fresh Mueller Hinton Brothat 1:50 and 1:100 for S. aureus and E. coli, respectively. Growth at 37°C. was continued as described above until the absorbance measured at 600nm reached 0.7-0.9 and 0.3-0.45 for S. aureus and E. coli, respectively.At this point, cells were harvested by centrifugation (10 min—5000×g—4°C.) and suspended in fresh Mueller Hinton Broth at a concentration of1×10⁸ CFU/ml.

Measurement of Antimicrobial Effect

Solutions of raw materials under evaluation (ingredients A and B) wereprepared in ethanol and then serially diluted in the desiredconcentration into 96-well microtiter plates (10 μl per well). Columns1, 10, 11 and 12 received only 10 μl ethanol without any testingmaterial. The final concentration of ethanol was 5% w/v for all wells.

Then, 90 μl of cell suspension as prepared above were added to each wellof the microtiter plate, with the exception of column 12 which received90 μl of Mueller Hinton Broth. The final volume of each well was broughtto 200 μl with Mueller Hinton Broth. Each plate was sealed and incubatedat 37° C. for 24 hours, under agitation (160 rpm). After incubation,plate reading was performed visually by recording wells with visiblebacterial growth. Each combination of materials was tested intriplicate. Turbidity due to potential precipitation of raw materialswas taken into account by scoring plates containing identical rawmaterial concentrations, without bacteria.

Results

Based on the test described above, the following combinations of rawmaterials were found to be antimicrobially active on E. coli DSMZ 1103:

TABLE 1 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 2-isopropyl-5-methylphenol as ingredient B.Concentration (ppm) Ingredient A Ingredient B FIC 600 0 1.000 300 1500.750 150 150 0.500 75 300 0.625 0 600 1.000

TABLE 2 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 2-isopropyl-5-methylphenol as ingredient B.Concentration (ppm) Ingredient A Ingredient B FIC 800 0 1.000 400 250.563 400 50 0.625 200 100 0.500 100 200 0.625 50 400 0.563 25 400 0.5310 800 1.000

TABLE 3 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 3-neopentylpyridine as ingredient B. Concentration(ppm) Ingredient A Ingredient B FIC 300 0 1.000 150 75 0.625 75 75 0.37575 150 0.500 75 300 0.750 0 600 1.000

TABLE 4 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 3-neopentylpyridine as ingredient B. Concentration(ppm) Ingredient A Ingredient B FIC 800 0 1.000 400 25 0.531 400 500.563 400 100 0.625 400 200 0.750 200 400 0.750 100 400 0.625 50 8001.063 25 800 1.031 0 800 1.000

TABLE 5 FIC of a composition comprising gamma-dodecalactone asingredient A and 1,3-Benzodioxole-5-carbaldehyde as ingredient B.Concentration (ppm) Ingredient A Ingredient B FIC 2400 0 1.000 1200 3000.750 600 300 0.500 300 600 0.625 150 600 0.563 75 600 0.531 0 12001.000

TABLE 6 FIC of a composition comprising gamma-dodecalactone asingredient A and 4-Methoxybenzaldehyde as ingredient B. Concentration(ppm) Ingredient A Ingredient B FIC 1200 0 1.000 600 150 0.625 300 1500.375 150 300 0.375 150 600 0.625 0 1200 1.000

TABLE 7 FIC of a composition comprising(Z)-3,7-Dimethyl-2,6-octadien-1-ol as ingredient A andgamma-dodecalactone as ingredient B. Concentration (ppm) Ingredient AIngredient B FIC 1200 0 1.000 600 75 0.563 600 150 0.625 300 300 0.500150 300 0.375 150 600 0.625 0 1200 1.000

TABLE 8 FIC of a composition comprisingcis-4(Isopropyl)cyclohexanemethanol as ingredient A and4-Methoxybenzaldehyde as ingredient B. Concentration (ppm) Ingredient AIngredient B FIC 9600 0 1.000 4800 150 0.625 2400 150 0.375 1200 1500.250 600 150 0.188 600 300 0.313 300 600 0.531 150 600 0.516 0 12001.000Based on the test described above, the following combinations of rawmaterials were found to be antimicrobially active on S. aureus DSMZ1104:

TABLE 9 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 3-neopentylpyridine as ingredient B. Concentration(ppm) Ingredient A Ingredient B FIC 600 0 1.00 300 75 0.75 150 75 0.5075 75 0.38 75 150 0.63 0 300 1.00

TABLE 10 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 3-neopentylpyridine as ingredient B. Concentration(ppm) Ingredient A Ingredient B FIC 800 0 1.00 800 25 1.02 800 50 1.03800 100 1.06 800 200 1.13 400 400 0.75 200 800 0.75 100 800 0.63 50 16001.06 25 1600 1.03 0 1600 1.00

TABLE 11 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 2-methylhexan-3-one oxime as ingredient B.Concentration (ppm) Ingredient A Ingredient B FIC 1200 0 1.00 600 1500.531 600 300 0.563 600 600 0.625 300 1200 0.500 150 2400 0.625 75 24000.563 0 4800 1.00

TABLE 12 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and 2-methylhexan-3-one oxime as ingredient B.Concentration (ppm) Ingredient A Ingredient B FIC 800 0 1.000 800 501.016 800 100 1.031 800 200 1.063 800 400 1.125 800 800 1.250 400 16001.000 200 1600 0.750 100 1600 0.625 50 3200 1.063 25 3200 1.031 0 32001.00

TABLE 13 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and α-terpineol as ingredient B. Concentration (ppm)Ingredient A Ingredient B FIC 2400 0 1.00 1200 75 0.56 1200 150 0.63 600300 0.50 300 600 0.63 0 1200 1.00

TABLE 14 FIC of a composition comprising (2E,6Z)-nona-2,6-dien-1-ol asingredient A and α-terpineol as ingredient B. Concentration (ppm)Ingredient A Ingredient B FIC 800 0 1.00 800 25 1.02 800 50 1.03 800 1001.06 800 200 1.13 800 400 1.25 400 800 1.00 200 800 0.75 100 1600 1.1350 1600 1.06 25 1600 1.03 0 1600 4.00

TABLE 15 FIC of a composition comprising gamma-dodecalactone asingredient A and 4-Methoxybenzaldehyde as ingredient B. Concentration(ppm) Ingredient A Ingredient B FIC 1200 0 1.00 600 150 0.52 600 3000.53 600 600 0.56 300 1200 0.38 300 2400 0.50 150 4800 0.63 75 4800 0.560 9600 1.00

TABLE 16 FIC of a composition comprising 1,3-Benzodioxole-5-carbaldehydeas ingredient A and 4-Methoxybenzaldehyde as ingredient B. Concentration(ppm) Ingredient A Ingredient B FIC 1200 0 1.00 600 75 0.56 300 150 0.38150 150 0.25 75 300 0.31 75 600 0.56 0 1200 1.00Those tables demonstrate that the above compositions present anantimicrobial synergistic effect as the FIC of those compositions arebelow or equal to 1.

Example 2

Antibacterial Effect of Compositions According to Some Aspects PresentedHerein in a Liquid Soap Base

Preparation of Bacterial Solutions

Bacterial solutions of the two strains, E. coli DSMZ 1103 and S. aureusDSMZ 1104, were prepared for BCT test as follows. Stock cultures storedat −80° C. were sub-cultured onto Tryptic Soy Agar (TSA) agar platemedia, and incubated at 37° C. for 24 h to obtain single colonies.Single colonies of the primary cultures were streaked onto TSA slant andincubate it at 37° C. incubator for 24 h. Bacterial lawns of the slantculture were collected in PBS buffer to make suspensions with the targetlevel of 1-5×10⁸ CFU/mL. The 1:100 dilution of each cell suspension inPBS buffer was used as the bacterial solutions for the BCT test.

Preparation of Test Samples

Test samples of base with synergistic binary mixtures were prepared asfollows. Raw materials of the synergistic binary mixtures (Table 17)were mixed with the liquid soap base PGK-10-003 (Table 18). Aliquots(2.5 g) of each mixture were weighed into 20 ml glass tube with astirrer bar, and added with equal amount of MilliQ water to make 50%suspension as the test samples for the BCT test.

TABLE 17 Compositions tested. Tested against E. coli DSMZ 1103 Testedagainst S. aureus DSMZ 1104 0.5% (2E,6Z)-nona-2,6-dien-1-ol + 0.4%(2E,6Z)-nona-2,6-dien-1-ol + 0.5% 2-isopropyl-5-methylphenol 0.2%2-isopropyl-5-methylphenol 0.6% (2E,6Z)-nona-2,6-dien-1-ol + 0.6%(2E,6Z)-nona-2,6-dien-1-ol + 0.6% 2-isopropyl-5-methylphenol 0.3%2-isopropyl-5-methylphenol 0.5% (2E,6Z)-nona-2,6-dien-1-ol + 0.18%(2E,6Z)-nona-2,6-dien-1-ol + 0.5% 3-neopentylpyridine 0.72%2-methylhexan-3-one oxime 0.6% (2E,6Z)-nona-2,6-dien-1-ol + 0.3%(2E,6Z)-nona-2,6-dien-1-ol + 0.6% 3-neopentylpyridine 1.2%2-methylhexan-3-one oxime 0.36% (2E,6Z)-nona-2,6-dien-1-ol + 0.36%3-neopentylpyridine

TABLE 18 Liquid soap base Composition % Water 60.1 Sodium benzoate 0.5Sodium laureth sulfate 24.0 Coco glucoside 4.0 PEG-7 glyceryl cocoate2.0 Coco-betaine 6.0 Sodium chloride 2.0 Citric acid (50%) 0.4 PEG-40Hydrogenated castor oil 0.5BCT Test

BCT tests were performed in the 20 ml sample tubes. Each sample tubewith 5 g of 50% sample suspension was placed onto a magnetic stirrer,and an aliquot of bacterial solution (100 μl) was added to the sampleand allowed for a contact of 45 sec during mixing. Then aliquots (0.5ml) of the mixture were transferred into 5 ml PBS, and further serialdilutions were made in 4.5 ml PBS. Aliquots (0.5 ml) of PBS dilutionswere plated onto duplicate plates of TSA plates using the pour platemethod. TSA plates were incubated at 37° C. for 48 h. After incubation,colonies on TSA plates were enumerated and log reduction of each samplewere calculated against the CFU counts of the control sample (MilliQwater).

Table 19 indicates that binary mixtures of (2E,6Z)-nona-2,6-dien-1-ol:2-isopropyl-5-methylphenol (1:1) at 0.5% and 0.6% and(2E,6Z)-nona-2,6-dien-1-ol: 3-neopentylpyridine (1:1) at 0.5% and 0.6%had 1.1, 1.8, 0.6, and 1.4 log reduction against E. coli DSMZ 1103,respectively, in 50% liquid soap base after a contact time of 45 sec.

TABLE 19 Antibacterial efficacy of compositions according to someaspects presented herein against E. coli DSMZ 1103 in 50% liquid soapbase Average log reduction ± SEM Composition of binary mixtures (n = 3)Without mixture 0.3 ± 0.3 0.25% (2E,6Z)-nona-2,6-dien-1-ol + 1.1 ± 0.20.25% 2-isopropyl-5-methylphenol 0.3% (2E,6Z)-nona-2,6-dien-1-ol + 1.8 ±0.2 0.3% 2-isopropyl-5-methylphenol 0.25% (2E,6Z)-nona-2,6-dien-1-ol +0.6 ± 0.1 0.25% 3-neopentylpyridine 0.3% (2E,6Z)-nona-2,6-dien-1-ol +1.4 ± 0.1 0.3% 3-neopentylpyridine

Table 20 shows that binary mixtures of (2E,6Z)-nona-2,6-dien-1-ol:2-isopropyl-5-methylphenol (2:1) at 0.3% and 0.45%,(2E,6Z)-nona-2,6-dien-1-ol: 2-methylhexan-3-one oxime (1:4) at 0.45% and0.75%, and (2E,6Z)-nona-2,6-dien-1-ol: 3-neopentylpyridine (1:1) at0.36% had 1.4 to 3.2 log reduction against S. aureus DSMZ 1104 in 50%liquid soap base after a contact time of 45 sec.

TABLE 20 Antibacterial efficacy of compositions according to someaspects presented herein against S. aureus DSMZ 1104 in 50% liquid soapbase Average log reduction ± SEM Composition of binary mixtures (n = 3)Without mixture 0.6 ± 0.2 0.2% (2E,6Z)-nona-2,6-dien-1-ol + 1.4 ± 0.40.1% 2-isopropyl-5-methylphenol 0.3% (2E,6Z)-nona-2,6-dien-1-ol + 2.2 ±0.5 0.15% 2-isopropyl-5-methylphenol 0.09% (2E,6Z)-nona-2,6-dien-1-ol +2.6 ± 0.2 0.36% 2-methylhexan-3-one oxime 0.15%(2E,6Z)-nona-2,6-dien-1-ol + 3.2 ± 0.1 0.6% 2-methylhexan-3-one oxime0.18% (2E,6Z)-nona-2,6-dien-1-ol + 1.9 ± 0.2 0.18% 3-neopentylpyridine

In conclusion, the data indicates that synergistic binary mixtures showsantibacterial effect against both E. coli DSMZ 1103 and S. aureus DSMZ1104 in a liquid soap base.

Table 21 showed that the measured bacterial log reduction observed usingof mixtures of 0.3% (2E,6Z)-nona-2,6-dien-1-ol+0.3% 3-neopentylpyridineis greater than the sum of the measured bacterial log reduction observedeither 0.3% (2E,6Z)-nona-2,6-dien-1-ol or 0.3% 3-neopentylpyridine inisolation. Similarly, the log reduction of mixtures of 0.3%(2E,6Z)-nona-2,6-dien-1-ol+0.3% 2-isopropyl-5-methylphenol is greaterthan that of 0.3% (2E,6Z)-nona-2,6-dien-1-ol or 0.3%2-isopropyl-5-methylphenol.

TABLE 21 Comparison of the antibacterial efficacy of synergistic binarymixture with that of single materials against E. coli DSMZ 1103 in 50%liquid soap base Average log reduction ± SEM Composition of binarymixtures (n = 2) Without mixture 0.0 ± 0.0 0.3%(2E,6Z)-nona-2,6-dien-1-ol + 1.4 ± 0.1 0.3% 3-neopentylpyridine 0.3%(2E,6Z)-nona-2,6-dien-1-ol + 1.8 ± 0.2 0.3% 2-isopropyl-5-methylphenol0.3% (2E,6Z)-nona-2,6-dien-1-ol 0.3 ± 0.2 0.3% 3-neopentylpyridine 0.3 ±0.2 0.3% 2-isopropyl-5-methylphenol 0.4 ± 0.0

Example 3

Antibacterial Effect of Compositions According to Some Aspects PresentedHerein in a Roll-on Deodorant Base

Preparation of Bacterial Solutions

Bacterial solution of C. xerosis ATCC 373 strain was prepared for BCTtest as follows. Stock cultures stored at −80° C. were subcultured ontoTryptic Soy Agar media with 0.5% Tween 80 (TSA-TW80), and incubated at37° C. for 48 h. The primary cultures were subcultured onto TSA-TW80again to prepare the secondary cultures. Single colonies of secondaryculture were inoculated into 30 ml of Brain Heart Infusion (BHI) brothwith 0.5% Tween 80 (BHI-TW80), and incubated at 37° C. 180 rpm for 24 h.Aliquots (1 ml) of the 24 h culture were inoculated into 30 ml of freshBHI-TW80 broth, and incubated at 37° C. 180 rpm for 48 h. Aliquots (2-3ml) of the 48 h culture were inoculated into four 50 ml of freshBHI-TW80 broth medium, and incubated at 37° C. 180 rpm for 4-6 hrs. Whenthe OD reached the target value of 1.6, cells were harvested bycentrifugation at 5000 rpm for 10 min, and then resuspended in the samefresh broth media to a target concentration of 10⁹ to 10¹⁰ cfu/mL. Thissuspension was used as the bacterial solution for the BCT test.

Preparation of Test Samples

Test samples of base with synergistic binary mixtures were prepared asfollows. Raw materials of the synergistic binary mixtures were weighed(Table 22), and mixed with 0.3 g PEG-40 Hydrogenated Castor Oil and 9.57g deodorant roll on base (Table 23).

TABLE 22 Compositions tested. Weight of raw materials % in test sample(2E,6Z)-nona-2,6-dien-1-ol 40 mg + 0.4% (2E,6Z)-nona-2,6-dien-1-ol +2-isopropyl-5-methylphenol 20 mg 0.2% 2-isopropyl-5-methylphenol(2E,6Z)-nona-2,6-dien-1-ol 24 mg + 0.24% (2E,6Z)-nona-2,6-dien-1-ol +2-isopropyl-5-methylphenol 24 mg 0.24% 2-isopropyl-5-methylphenol(2E,6Z)-nona-2,6-dien-1-ol 12 mg + 0.12% (2E,6Z)-nona-2,6-dien-1-ol +2-methylhexan-3-one oxime 12 mg 0.48% 2-methylhexan-3-one oxime(2E,6Z)-nona-2,6-dien-1-ol 20 mg + 0.2% (2E,6Z)-nona-2,6-dien-1-ol +Terpineol 40 mg 0.4% Terpineol (2E,6Z)-nona-2,6-dien-1-ol 24 mg + 0.24%(2E,6Z)-nona-2,6-dien-1-ol + 3-neopentylpyridine 24 mg 0.24%3-neopentylpyridine

TABLE 23 Roll-on deodorant soap base Composition % Water deionised 50 2NATROSOL 250 H Hydroxyethylcellulose 0.7 Ethyl alcohol 95° 401,2-Propylene glycol 5BCT Test

BCT tests were performed in 15 ml sample tubes. Aliquots (0.9 g) of eachsample were weighed into the tube, and an aliquot of bacterial solution(100 μl) was added to the sample and allowed for a contact time of 120sec with constant mixing. At the end of the contact time, aliquots (9ml) of BHI broth were added to the tube. The suspensions were mixed wellby vortexing, and further 1:10 serial dilutions were made in 9.9 ml BHI.Aliquots (1 ml) of BHI dilutions were plated onto duplicate plates ofTSA-TW80 using pour plate methods. TSA-TW80 plates were incubated at 37°C. for 2-3 days. After incubation, colonies on TSA-TW80 plates wereenumerated and log reduction of each sample were calculated against theCFU counts of the control sample (BHI).

Table 24 indicates that the addition of binary mixtures of(2E,6Z)-nona-2,6-dien-1-ol: 2-isopropyl-5-methylphenol (1:2) at 0.54%,(2E,6Z)-nona-2,6-dien-1-ol: 2-isopropyl-5-methylphenol (1:1) at 0.432%,(2E,6Z)-nona-2,6-dien-1-ol: 2-methylhexan-3-one oxime (1:4) at 0.54%,(2E,6Z)-nona-2,6-dien-1-ol: Terpineol (1:4) at 0.54%,(2E,6Z)-nona-2,6-dien-1-ol: 3-neopentylpyridine (1:1) at 0.432% in the90% deodorant roll-on base improve the antimicrobial effect of baseagainst C. xerosis ATCC 373 after a contact time of 120 sec.

TABLE 24 Antibacterial efficacy of synergistic binary mixtures againstC. xerosis ATCC 373 in 90% roll-on deodorant base Average log reduction± SEM Composition of binary mixtures (n = 2) Without mixture 5.4 ± 0.00.36% (2E,6Z)-nona-2,6-dien-1-ol + 6.6 ± 0.2 0.18%2-isopropyl-5-methylphenol 0.216% (2E,6Z)-nona-2,6-dien-1-ol + 6.3 ± 0.20.216% 2-isopropyl-5-methylphenol 0.108% (2E,6Z)-nona-2,6-dien-1-ol +6.1 ± 0.2 0.432% 2-methylhexan-3-one oxime 0.18%(2E,6Z)-nona-2,6-dien-1-ol + 6.4 ± 0.3 0.36% Terpineol 0.216%(2E,6Z)-nona-2,6-dien-1-ol + 5.8 ± 0.2 0.216% 3-neopentylpyridine

Table 25 shows that mixture of (0.216% (2E,6Z)-nona-2,6-dien-1-ol+0.216%2-isopropyl-5-methylphenol) had greater log reduction than that of0.216% (2E,6Z)-nona-2,6-dien-1-ol or 0.216% 2-isopropyl-5-methylphenol.However, a mixture of (0.216% (2E,6Z)-nona-2,6-dien-1-ol+0.216%3-neopentylpyridine) had similar log reduction as that of 0.216%(2E,6Z)-nona-2,6-dien-1-ol or 0.216% 3-neopentylpyridine.

TABLE 25 Comparison of the antibacterial efficacy of synergistic binarymixtures with that of single materials against C. xerosis ATCC 373 in90% roll-on deodorant base Composition of binary mixtures Log reductionWithout mixture 5.5 0.216% (2E,6Z)-nona-2,6-dien-1-ol + 6.5 0.216%2-isopropyl-5-methylphenol 0.216% (2E,6Z)-nona-2,6-dien-1-ol + 5.90.216% 3-neopentylpyridine 0.216% (2E,6Z)-nona-2,6-dien-1-ol 5.7 0.216%2-isopropyl-5-methylphenol 6.0 0.216% 3-neopentylpyridine 5.9

What is claimed is:
 1. A composition comprising nona-2,6-dien-1-ol in anamount between 75 ppm to 200 ppm and at least one ingredient selectedfrom 3-neopentylpyridine in an amount between 75 ppm to 150 ppm, and2-methylhexan-3-one oxime; wherein the ingredients are present in anamount sufficient to provide an antimicrobial effect, and wherein theantimicrobial effect is an inhibition of growth of a bacterial strainselected from the group consisting of C. xerosis, S. aureus and E. coli.2. The composition of claim 1, further comprising at least oneingredient selected from the group consisting of a perfumery carrier, aperfuming co-ingredient and mixtures thereof; and optionally at leastone perfumery adjuvant.
 3. The composition of claim 2, formulated as aconsumer product, wherein the consumer product is a fabric care product,a body-care product, an air care product or a home care product.
 4. Thecomposition of claim 1, wherein the amount of the 2-methylhexan-3-oneoxime is from 1000 to 1200 ppm.
 5. The composition of claim 1,comprising nona-2,6-dien-1-ol and 3-neopentylpyridine.
 6. Thecomposition of claim 1, wherein the amount of the nona-2,6-dien-1-ol isfrom 75 ppm to 150 ppm.
 7. The composition of claim 3, wherein thebody-care product is a perfume or a skin-care product.